RxDoctor Payments Data

Katie Veltman

Nurse Practitioner · Naples, FLNPI 1114623311

Payments from drug & device makers

$8,780in general payments, 2019–2025

Across 201 payments — averaging $43.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • AbbVie$1K
  • Madrigal Pharmaceuticals$603
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$499
  • Phathom Pharmaceuticals, Inc.$429
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$2,52429%
  • Food & beverage$6,25671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,780 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$133,536
Medicare patients
820
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase15$67,445
XifaxanRifaximin27$61,647
LinzessLinaclotide32$26,188
Mesalamine11$5,292
Pantoprazole Sodium296$3,991
CholestyramineCholestyramine (With Sugar)36$2,429
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,425
Omeprazole114$1,913
Famotidine124$1,730
Budesonide DrBudesonide14$1,444
Esomeprazole Magnesium36$961
Dicyclomine Hcl30$720
Sucralfate16$567
ConstuloseLactulose11$413
Amitriptyline Hcl12$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$173$67,44515 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$499$61,64727 claims
AbbVieLinzess$1,123$26,18832 claims
Braintree Laboratories, Inc.Sutab$67$2,42515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →